Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

 Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Medtronic Reports Results of Symplicity Renal Denervation System in Two Studies for Hypertensive Heart Diseases

Shots:

  • The two studies include investigator-led study & Global SYMPLICITY Registry results involves the assessing of Symplicity renal denervation system vs sham in 80 & 2,600 patients with uncontrolled hypertension
  • Collective results: atrial fibrillation (AF) occurrence (19% vs 47%); reductions in both office and ambulatory blood pressure (16.5 mm Hg OSBP and 8.9 mm Hg 24H systolic ABPM), sustained reduction in BP in diabetes, ISH, CKD; safe & effective, presented at EuroPCR, 2019
  • Medtronic’s Symplicity is also evaluated 70-patient SYMPLICITY AF study assessing renal denervation system in patients with paroxysmal and persistent atrial fibrillation and is approved in 50+ countries

Click here to read full press release/ article | Ref: Medtronic | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post